To investigate whether the high expression of IDO1 and concurrently elevated Kyn serum levels contribute to changes in the microenvironment and thereby impact on CLL development, we performed treatment studies in TCL1 AT mice using two compounds that were described to inhibit IDO1. The gene discussed is IDO1; the disease is B-cell chronic lymphocytic leukemia.